T Cell Lymphoblastic Lymphoma Showing Abberant Synaptophysin Expression in a Child

Koçer, Nazım Emrah; Hasbay, Bermal; Kayaselçuk, Fazi̇let

doi:10.4274/tjh.galenos.2019.2019.0307

Cited by 3 publications

(5 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of which, ALL accounts for 75% of acute leukemia in this patient group. 5 That is evident in the patients' characteristics, as 55.4% of ALL cases are diagnosed at an age less than 20 years, 28% are diagnosed at 45 years or older and only 12.3% patients are diagnosed at 65 years or more. According to the origin of the malignant clone, arising either from B or T lymphoid progenitors, ALL is classified as B-ALL or T-ALL, respectively, the former entity accounting for 80-85% and the latter for 20-25% of ALL.…”

Section: Discussionmentioning

confidence: 98%

“…14 After achieving remission, T-ALL has high incidence of relapse with an Overall Survival (OS) of 50-60% in adult patients. 5 With the application of risk-adapted therapy and increased supportive care, the survival rate of ALL among children has increased from 57 to 92%, however in 20% of children, relapses can still occur 23 , which have also been associated with poor outcomes. The incidence of high-risk leukemia and relapse is higher in adults (40-50%) 24 as compared to children.…”

Section: Discussionmentioning

confidence: 99%

“…4 T-ALL has a high relapse rate after achieving remission with chemotherapy, which contributes to the inferior overall survival (OS) rate of 50-60% in adult patients. 5 However, with the implementation of risk-adapted therapy and improved supportive care, the survival rate of T-ALL in children has increased from 57% to 92%. 6,7 However, a lower survival rate is reported in developing countries, ranging from 30-70%.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Early response and outcomes of bone marrow to chemotherapy in T-Cell Acute Lymphoblastic Leukemia

AlMoshary,

Mahmoud Altahan,

Fayez Alswayyed

2024

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: To evaluate the outcomes (relapse and mortality rate) and response of the bone marrow in early stages after combination chemotherapy in patients with T-cell Acute Lymphoblastic Leukemia (T-ALL). Methods: A descriptive cross-sectional study was conducted at King Fahad Medical City, from January 2021 to December 2022, to evaluate bone marrow findings at the time of diagnosis and post-chemotherapy in 26 patients diagnosed with T-ALL. The study included all patients diagnosed with T-ALL of any age group during the study period. The patients’ bone marrows were examined at 0 days of treatment (diagnosis work-up), followed by examination at day 15 post induction therapy, and day 30 after treatment. Results: In this study, 26 cases of T-lymphoblastic leukemia were analyzed. The mean age at diagnosis was 15.69±14.28 years, and eight cases had central nervous system involvement. The majority of cases (88.5%) were positive for Cytoplasmic-CD3 and CD7. Positive findings by fluorescence in situ hybridization (FISH) were: T cell receptor (TCR) α/δ in 6 (23.1%) of the patients, CDNK2A/CEP9 in five (19.2%), and TRCB in one (3.8%). Examination of the bone marrow on day 15 revealed a decrease in blasts to ≤1% in nine patients, and to ≤1% in 19 patients on day 30 post-therapy. Relapse was recorded in five (19.23%) patients. Three (11.53%) patients did not survive during treatment, of which two were <10 years old. The relapse rate for T-ALL was 19.23%, with an overall survival rate of about 64%. The overall mortality rate was 11.53%. Conclusion: The relapse rate for T-ALL in our study was approximately 19%, but the mortality rate was 11.5%. A substantial decrease in blast percentages was observed, suggesting a favorable initial reaction of the bone marrow to the combined chemotherapy. This suggests that the use of aggressive and more effective chemotherapy has led to better outcomes. doi: https://doi.org/10.12669/pjms.40.5.7584 How to cite this: AlMoshary M, Altahan SM, Alswayyed AF. Early response and outcomes of bone marrow to chemotherapy in T-Cell Acute Lymphoblastic Leukemia. Pak J Med Sci. 2024;40(5):---------. doi: https://doi.org/10.12669/pjms.40.5.7584 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Early response and outcomes of bone marrow to chemotherapy in T-Cell Acute Lymphoblastic Leukemia

AlMoshary,

Mahmoud Altahan,

Fayez Alswayyed

2024

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…-Linfoma linfoblástico con expresión aberrante de sinaptofisina, descrito por Nazım Emrah et al, en una paciente de sexo femenino de 9 años de edad con masa en mediastino anterior, derrame pleural y linfadenopatías. En biopsia se evidenció inmunofenotipo positivo para ALC, CD2, CD3, CD10, CD1a, TDT, sinaptofisina, con Ki67 del 90%, y negatividad para CD20, pancitoqueratina, CK19, cromogranina y CD56 22 .…”

Section: B Aunclassified

Rabdomiosarcoma alveolar con expresión aberrante de biomarcadores epiteliales y neuroendocrinos

Palencia-Palacio,

Romero-Rojas,

Parra-Medina

et al. 2023

GAMO

View full text Add to dashboard Cite

Antecedentes: El rabdomiosarcoma alveolar es un sarcoma con diferenciación de músculo esquelético que ocurre con mayor frecuencia en adolescentes y adultos jóvenes. Se considera de mal pronóstico. La ubicación más frecuente son las extremidades. Descripción del caso: Mujer de 78 años, quien presenta masa heterogénea en muslo izquierdo de ocho meses de evolución, alcanzando un tamaño de 11 cm de diámetro, con compromiso vascular. La biopsia mostró un RMSa con expresión aberrante de marcadores epiteliales y neuroendocrinos. Conclusiones: En la categoría de los RMSa es importante conocer el inmunofenotipo que los caracteriza, así como la expresión aberrante de marcadores epiteliales y neuroendocrinos.

show abstract

“…2,3 According to the current literature, KIT-positive mature B-cell neoplasms are extremely rare, and a case series of 1166 lymphomas identified only one case of B-cell lymphoma that showed KIT expression by immunohistochemistry. 4 Synaptophysin is a neuronal cell marker commonly expressed in neuroendocrine tumors, and it is an extremely rare finding in tumors of hematopoietic origin with only rare cases being reported in T-cell lineage neoplasms 5,6 and a subset of classic Hodgkin lymphoma in a recent study. 7 To the best of our knowledge, there is no reported case of synaptophysin expression in a B-cell non-Hodgkin lymphoma in the current literature yet.…”

mentioning

confidence: 99%

Unusual Expression of KIT (CD117) and Synaptophysin in a B-Cell Lymphoma

2023

View full text Add to dashboard Cite

T Cell Lymphoblastic Lymphoma Showing Abberant Synaptophysin Expression in a Child

Cited by 3 publications

References 3 publications

Early response and outcomes of bone marrow to chemotherapy in T-Cell Acute Lymphoblastic Leukemia

Early response and outcomes of bone marrow to chemotherapy in T-Cell Acute Lymphoblastic Leukemia

Rabdomiosarcoma alveolar con expresión aberrante de biomarcadores epiteliales y neuroendocrinos

Unusual Expression of KIT (CD117) and Synaptophysin in a B-Cell Lymphoma

Contact Info

Product

Resources

About